Sign inCreate account

Report workspace tools

NCT00991562COMPLETEDanonymous

An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma

Sponsor

Source record

ImmunoGen, Inc.

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

IMGN901

Indication / condition

AI-normalized

Multiple Myeloma

Intervention

Source record

IMGN901

Source & freshness

Source record

NCT ID

NCT00991562

Original source

ClinicalTrials.gov

Source last updated

Nov 21, 2014

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00991562

Title

An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma

Sponsor

ImmunoGen, Inc.

Status

COMPLETED

Phase

PHASE1

Condition raw

Multiple Myeloma

Condition normalized

Multiple Myeloma

Modality raw

Multiple Myeloma

Modality normalized

small molecule

Target raw

IMGN901

Target normalized

IMGN901

Interventions

IMGN901

Public preview

Source record

The purpose of this study is to test IMGN901 in combination with lenalidomide and dexamethasone every 28 days.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00991562

Status

COMPLETED

Phase

PHASE1

Sponsor

ImmunoGen, Inc.

Executive brief

Investment-Ready Snapshot

The purpose of this study is to test IMGN901 in combination with lenalidomide and dexamethasone every 28 days.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedNov 21, 2014
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00991562

Indication

Multiple Myeloma

Modality

small molecule

Target

IMGN901

Intervention

IMGN901

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.